Trial · NCT03595488
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | SNOT 22 Score | From baseline to completion of study(7 months total) | This is a patient-reported outcome score for chronic rhinosinusitis with or without nasal polyposis |
| Secondary | UPSIT | From baseline to completion of study( 7 months total) | Univ. of Pennsylvania smell identification test |
| Secondary | Lund Mackay score | From baseline to completion of study( 7 months total) | Objective score for CT sinus imaging, this is a widely used method for radiologic staging of chronic rhinosinusitis. |
| Secondary | ACT score | From baseline to completion of study( 7 months total) | Validated asthma control test, a series of 5 questions related to patient's asthma control over the previous 4 weeks. |
| Secondary | Asthma Mini-AQLQ, 15 questions to assess quality of life. This assessment takes approximately 4-5 minutes to complete the questions. | From baseline to completion of study( 7 months total) | Validated asthma quality of life score |
| Secondary | Change in FEV1 | From baseline to completion of study( 7 months total) | Forced expiratory volume in first second from spirometry |
| Secondary | Change in FeNO | From baseline to completion of study( 7 months total) | Exhaled nitric oxide |
| Secondary | Eosinophil count | From baseline to completion of study( 7 months total) | Absolute eosinophil count |
| Secondary | Total serum IgE | From baseline to completion of study( 7 months total) | Total IgE |
| Secondary | Serum tryptase | From baseline to completion of study( 7 months total) | Biomarker |
| Secondary | Serum TARC (thymus and activation regulated cytokine) | From baseline to completion of study( 7 months total) | Biomarker |
| Secondary | Serum prostaglandin D2 | From baseline to completion of study( 7 months total) | Biomarker |
| Secondary | 24 hour urinary leukotriene E4 | From baseline to completion of study( 7 months total) | Biomarker |
| Secondary | To assess the safety and tolerability of dupilumab | From baseline to completion of study( 7 months total) | Adverse events |
| Secondary | To assess cumulative dose of systemic steroids | From baseline to completion of study( 7 months total) | Impact on systemic steroids |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03595488/registered